Early Impact of Human Papillomavirus Vaccination on Cervical Neoplasia--Nationwide Follow-up of Young Danish Women

Baldur-Felskov, Birgitte; Dehlendorff, Christian; Munk, Christian; Kjær, Susanne K.

doi:10.1093/jnci/djt460

Cited by 165 publications

(135 citation statements)

References 26 publications

Supporting

Mentioning

130

Contrasting

Unclassified

Order By: Relevance

“…A study in Australia (Crowe et al 2014) showed a 43% decrease of atypical cells and a 62% decrease of HSIL in women aged 22-25 years with three vaccinations (after a lapse of 7 years). Similarly, a report in Denmark (Baldur-Felskov et al 2014) on uterine cervical cancer screening for women aged 20-21 years showed that atypical cells, CIN2 and CIN3 decreased by about 60%, 73%, and 80%, respectively. A study in Scotland (Pollock et al 2014) also showed that CIN3 decreased by about 55% after vaccination.…”

Section: Discussionmentioning

confidence: 81%

Lower Incidence of Cervical Intraepithelial Neoplasia among Young Women with Human Papillomavirus Vaccination in Miyagi, Japan

Ozawa¹,

Itō

Tase

et al. 2017

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

The Japanese national immunization programme for Human Papillomavirus (HPV) started in 2010. Vaccination rates increased up to 70% in women in the 1996-1999 birth. However, the proactive recommendation for HPV vaccine was suspended in 2013, following repeated media reports of adverse events. Vaccination rates plumped to less than 1% in women born since 2002. In this study, incidence of abnormal cytology and histology was examined in terms of HPV vaccination among 5,924 women aged 20 to 24 years in the fiscal year (FY) 2014 and 2015. The total rate of vaccination was 16.9% (1,002/5,924). In case of FY 2015, the rates of vaccination were 59.26%, 49.68%, 11.97%, 9.08%, and 4.58% in those aged 20, 21, 22, 23, and 24 years old, respectively. The rates of high-grade squamous intraepithelial lesion (HSIL) or worse were 0.20% (2/1,002) in women with HPV vaccination and 1.14% (56/4,922) in those without HPV vaccination, indicating a significant reduction of 82.46% with vaccination (P < 0.0001). The rates of cervical intraepithelial neoplasia (CIN) 1+ were 0.80% (8/1,002) in women with vaccination and 2.28% (112/4,922) in those without vaccination. The reduction rate of CIN1+ was 64.91% (P = 0.0025). The rates of CIN2+ were 0.10% (1/1,002) with vaccination and 0.69% (34/4,922) without vaccination. The reduction rate of CIN2+ was 85.51% (P = 0.0261). Our data are the first to demonstrate a significant reduction of CIN2+ cases in an Asian population. Scientific discussion is needed to restart the proactive recommendation for HPV vaccine in Japan.

show abstract

Section: Discussionmentioning

confidence: 81%

Lower Incidence of Cervical Intraepithelial Neoplasia among Young Women with Human Papillomavirus Vaccination in Miyagi, Japan

Ozawa¹,

Itō

Tase

et al. 2017

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

show abstract

“…12 The quadrivalent HPV (6/11/16/18) virus-like particle (qHPV) vaccine is highly efficacious in preventing infection and cervical, vaginal, vulvar, and anal dysplasia caused by HPV 6/11/16/18 as well as HPV 6/11-related condyloma, [13][14][15][16] and the bivalent HPV (16/18) vaccine is highly efficacious against HPV 16/18-related infection and cervical dysplasia. 17 Postlicensure studies have shown a rapid decrease in the incidence of high-grade cervical abnormalities, [18][19][20][21] prevalence of vaccine HPV types, [22][23][24][25][26] and incidence of genital warts [27][28][29][30][31] in vaccinees. Data have shown that prophylactic HPV vaccination is generally safe and well tolerated.…”

Section: What This Study Addsmentioning

confidence: 99%

Immunogenicity and Safety of a 9-Valent HPV Vaccine

et al. 2015

View full text Add to dashboard Cite

OBJECTIVES: Prophylactic vaccination of youngwomen aged 16 to 26 years with the 9-valent (6/11/16/18/31/33/45/52/58) human papillomavirus (HPV) virus-like particle (9vHPV) vaccine prevents infection and disease. We conducted a noninferiority immunogenicity study to bridge the findings in young women to girls and boys aged 9 to 15 years.METHODS: Subjects (N = 3066) received a 3-dose regimen of 9vHPV vaccine administered at day 1, month 2, and month 6. Anti-HPV serologic assays were performed at day 1 and month 7. Noninferiority required that the lower bound of 2-sided 95% confidence intervals of geometric mean titer ratios (boys:young women or girls:young women) be .0.67 for each HPV type. Systemic and injection-site adverse experiences (AEs) and serious AEs were monitored.RESULTS: At 4 weeks after dose 3, .99% of girls, boys, and young women seroconverted for each vaccine HPV type. Increases in geometric mean titers to HPV types 6/11/16/18/ 31/33/45/52/58 were elicited in all vaccine groups. Responses in girls and boys were noninferior to those of young women. Persistence of anti-HPV responses was demonstrated through 2.5 years after dose 3. Administration of the 9vHPV vaccine was generally well tolerated. A lower proportion of girls (81.9%) and boys (72.8%) than young women (85.4%) reported injection-site AEs, most of which were mild to moderate in intensity.CONCLUSIONS: These data support bridging the efficacy findings with 9vHPV vaccine in young women 16 to 26 years of age to girls and boys 9 to 15 years of age and implementing genderneutral HPV vaccination programs in preadolescents and adolescents.WHAT'S KNOWN ON THIS SUBJECT: Prophylactic vaccination of young women 16 to 26 years of age with the 9-valent human papillomavirus (HPV)-like particle (9vHPV) vaccine prevents infection and disease with vaccine HPV types.WHAT THIS STUDY ADDS: These data support bridging the efficacy findings with 9vHPV vaccine in young women 16 to 26 years of age to girls and boys 9 to 15 years of age and implementation of gender-neutral HPV vaccination programs in preadolescents and adolescents.

show abstract

“…In addition, low vaccine coverage may jeopardize the expected public health benefits and cost-effectiveness of qHPV vaccine programs. As there are currently few studies on the real-world effects of the qHPV vaccine [17][18][19][20][21] and none on the population-level impact of qHPV vaccine programs on the burden of disease, we undertook a populationbased, retrospective cohort study to assess the impact of the qHPV vaccine and Ontario's qHPV vaccination program on the incidence of cervical dysplasia and AGW among adolescent girls.…”

Section: What This Study Addsmentioning

confidence: 99%

The Early Benefits of Human Papillomavirus Vaccination on Cervical Dysplasia and Anogenital Warts

Smith¹,

Strumpf

Kaufman³

et al. 2015

Pediatrics

View full text Add to dashboard Cite

show abstract

Early Impact of Human Papillomavirus Vaccination on Cervical Neoplasia--Nationwide Follow-up of Young Danish Women

Abstract: Six years after licensure of the quadrivalent HPV vaccine in Denmark, a reduced risk of cervical lesions is observed at the population level.

Cited by 165 publications

References 26 publications

Lower Incidence of Cervical Intraepithelial Neoplasia among Young Women with Human Papillomavirus Vaccination in Miyagi, Japan

Lower Incidence of Cervical Intraepithelial Neoplasia among Young Women with Human Papillomavirus Vaccination in Miyagi, Japan

Immunogenicity and Safety of a 9-Valent HPV Vaccine

The Early Benefits of Human Papillomavirus Vaccination on Cervical Dysplasia and Anogenital Warts

Contact Info

Product

Resources

About